Som med anden medicin mod hiv kan patienter, der får Prezista, udvikle lipodystrofi (forandringer i kropsfedtets fordeling), osteonekrose (knoglevævsdød) eller immunreaktiveringssyndrom (symptomer, der svarer til en infektion og skyldes, at immunsystemet genvinder sin funktion).
As with other anti-HIV medicines, patients taking Prezista may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).